Navigation Links
Fuisz Pharma LLC Develops a New Generation of Oral Solid Dosage Form Shapes That Facilitate Swallowing and Esophageal Transit
Date:4/6/2011

MIAMI, April 6, 2011 /PRNewswire/ -- Fuisz Pharma LLC announced today a new generation of solid dosage form designs that facilitate swallowing and esophageal transit.

Clinical studies demonstrate that these new designs and principles thereof speed esophageal transit by 80%, ease the swallowing experience, and reduce the incidence of esophageal transit failure, as compared with the conventional tablet designs currently used.

Joseph Fuisz, managing partner of Fuisz Pharma stated: "We stand at a crossroads where there is a keen understanding of the importance of compliance and the challenges to compliance posed by an aging population throughout the developed world.  At the same time however, cost containment pressures -- manifested primarily in reimbursement schemes -- make it challenging for branded pharma to broadly adopt value added drug delivery technologies."

"Our intention with this effort was to take existing tablet granulations and approach the question of form – as it relates to swallowability – from first principles.  The results were quite astonishing in that we demonstrated the ability to make enormous improvements in the swallowability of conventionally manufactured dosage forms.  Literally, we are able to take the existing granulation and stamp out a dramatically better performing product.  This advance also applies to capsules.  We are pursuing new dosage form classification for these next generation shapes in order to properly recognize their therapeutic value and to maximize the life cycle management benefit to our partners."

Richard C. Fuisz, M.D., a founder of Fuisz Pharma, commented: "I have had the privilege of making substantial contributions to the development and commercialization of orally dissolving tablets and orally soluble films, both of which were granted new dosage form classification to distinguish them from the then existing dosage forms.  Our new solid dosage form designs will represent my third oral dosage form and will ultimately prove to be the most important due to their extraordinary combination of high performance and ease of manufacture."

The breakthrough is backed by clinical studies as well as in vitro studies and will change the way tablets and capsules look in the future. The work includes the end product as well as the press and mold designs to produce them. The inventions have been filed with the Unite States Patent and Trademark Office through multiple filings .

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami.  www.fuisz.com.


'/>"/>
SOURCE Fuisz Pharma LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz Pharma Releases Clinical Photos of Its Opioid Abuse Detection System
2. Fuisz Announces Issuance of Patent for the New Generation of Glucose and Other Analyte Analyzers
3. Fuisz Pharma Announces Acquisition of Key Anti Opiate Abuse Patent to Complement its Anti Opiate Abuse Platform
4. FUISZ Announces Advances in Devices and Solid Dosage Form
5. Fuisz Pharma Announces Novel Anti Abuse System for Opiates
6. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
7. Harnessing Patients Good Intentions Can Cut 33% of Americas Pharmacy-Related Waste
8. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
9. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
10. ACLJ Gets Win for Pro-Life Pharmacy Owners in Illinois After Lengthy Legal Battle
11. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Raises Target Price to $3.22
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... Patient warming ... of blood during surgeries, lowering the risks of neurological disorders ... of SSIs. The patient warming systems can be segmented into ... benefits in turn reduce the stay at hospitals thus, lowering ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying ... Va. "I thought that if the nebulizer had a more child-friendly design, then children ... , He developed the patent-pending NEBY to avoid the need to deliver medication via ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... will become Quality Insights beginning January 1, 2017. The name change aligns ... commitment to measuring and improving health care quality. , “We are very proud ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc ... Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: ... , Results of the comparative usability study demonstrate that a dictation-based method (“NLP ...
Breaking Medicine News(10 mins):